Bonnie L Bassler Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

REGN Quotes by TradingView

Bonnie L Bassler is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 1,382 shares of REGN, which is worth approximately $1.59 Million. The most recent transaction as insider was on Jan 03, 2023, when has been sold 165 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.38K
0% 3M change
10.83% 12M change
Total Value Held $1.59 Million

Bonnie L Bassler Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 03 2023
BUY
Grant, award, or other acquisition
-
165 Added 11.69%
1,247 Common Stock
Dec 08 2022
SELL
Open market or private sale
$169,822 $779.0 p/Share
218 Reduced 16.77%
1,082 Common Stock
Dec 08 2022
BUY
Exercise of conversion of derivative security
$83,047 $380.95 p/Share
218 Added 14.36%
1,300 Common Stock
Sep 09 2022
SELL
Open market or private sale
$451,269 $741.0 p/Share
609 Reduced 36.01%
1,082 Common Stock
Sep 09 2022
BUY
Exercise of conversion of derivative security
$229,404 $376.69 p/Share
609 Added 26.48%
1,691 Common Stock
Sep 08 2022
SELL
Open market or private sale
$1,780,342 $695.99 p/Share
2,558 Reduced 70.27%
1,082 Common Stock
Sep 08 2022
BUY
Exercise of conversion of derivative security
$1,002,531 $391.92 p/Share
2,558 Added 52.0%
2,361 Common Stock
Apr 07 2022
SELL
Open market or private sale
$899,000 $725.0 p/Share
1,240 Reduced 53.4%
1,082 Common Stock
Apr 07 2022
BUY
Exercise of conversion of derivative security
$472,378 $380.95 p/Share
1,240 Added 34.81%
2,322 Common Stock
Mar 30 2022
SELL
Open market or private sale
$868,000 $700.0 p/Share
1,240 Reduced 53.4%
1,082 Common Stock
Mar 30 2022
BUY
Exercise of conversion of derivative security
$472,378 $380.95 p/Share
1,240 Added 34.81%
2,322 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
191 Added 15.0%
1,082 Common Stock
Aug 16 2021
SELL
Open market or private sale
$767,970 $630.0 p/Share
1,219 Reduced 57.77%
891 Common Stock
Aug 16 2021
BUY
Exercise of conversion of derivative security
$459,185 $376.69 p/Share
1,219 Added 36.62%
2,110 Common Stock
Aug 05 2021
SELL
Open market or private sale
$1,535,400 $600.0 p/Share
2,559 Reduced 74.17%
891 Common Stock
Aug 05 2021
BUY
Exercise of conversion of derivative security
$1,002,923 $391.92 p/Share
2,559 Added 42.59%
3,450 Common Stock
Jul 01 2021
SELL
Open market or private sale
$1,470,850 $575.0 p/Share
2,558 Reduced 74.17%
891 Common Stock
Jul 01 2021
BUY
Exercise of conversion of derivative security
$1,002,531 $391.92 p/Share
2,558 Added 42.58%
3,449 Common Stock
Jan 04 2021
BUY
Grant, award, or other acquisition
-
248 Added 21.77%
891 Common Stock

Also insider at

RPRX
Royalty Pharma plc Healthcare
Director
CDTX
Cidara Therapeutics, Inc. Healthcare
Director
KLDO
Kaleido Biosciences, Inc. Healthcare
Director
BLB

Bonnie L Bassler

Director
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on REGN